Latest On Aravive, Inc (ARAV):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 13:53 EST | News | Aravive: Very Small Company With Late Stage Trial In Ovarian Cancer | N/A |  |
| 2023-05-11 02:13 EST | News | Aravive GAAP EPS of -$0.66 misses by $0.34, revenue of $1.49M beats by $1.07M | N/A | |
| 2023-03-15 23:40 EST | News | Aravive GAAP EPS of -$0.46, revenue of $1.47M | N/A | |
| 2023-03-01 08:01 EST | News | Aravive stock pops on FDA orphan drug status for batiraxcept to treat pancreatic cancer | N/A | |
| 2022-12-14 13:04 EST | News | Aravive: Down But Not Out With Pivotal Ovarian Data Due In 2023 | N/A | |
| 2022-11-29 21:09 EST | News | Aravive gains on FDA Fast Track status for lead program | N/A | |
| 2022-10-25 22:52 EST | News | Aravive to raise $41.5M in direct stock offering | N/A | |
| 2022-08-11 23:12 EST | News | Aravive Q2 GAAP EPS misses, revenue beats | N/A | |
| 2022-07-05 09:43 EST | News | Aravive appoints Robert Geller as CMO | N/A | |
| 2022-06-03 17:18 EST | News | Aravive appoints Rudy Howard as CFO | N/A | |
| 2022-05-25 12:47 EST | News | Aravive (ARAV) Investor presentations - Slideshow | N/A | |
| 2022-05-12 13:08 EST | News | Aravive GAAP EPS of -$0.62, revenue of $1.09M | N/A | |
| 2022-04-01 02:59 EST | News | Aravive GAAP EPS of -$0.62 misses by $0.02, revenue of $0.99M misses by $0.52M | N/A | |
| 2022-03-30 14:42 EST | News | Aravive launches ~$10M stock and warrant offering | N/A | |
| 2022-03-22 17:30 EST | News | Aravive names Scott Dove, Ph.D., as COO | N/A | |
| 2022-01-31 13:43 EST | News | Aravive begins dosing in phase 2 study of batiraxcept to treat kidney cancer | N/A | |
| 2022-01-04 09:30 EST | News | Aravive's Chairman Fred Eshelman invests $10M via stock purchase | N/A | |
| 2021-11-05 01:30 EST | News | Warning: ARAV is at high risk of performing badly | N/A | |
| 2021-10-28 17:02 EST | News | Aravive EPS misses by $0.07, beats on revenue | N/A | |
| 2021-08-09 23:29 EST | News | Aravive gets dosing underway in early-stage pancreatic adenocarcinoma study | N/A | |
| 2021-08-05 22:24 EST | News | Aravive EPS beats by $0.03, beats on revenue | N/A | |
| 2021-07-20 19:47 EST | News | Aravive shares surge on early-stage kidney cancer study data | N/A | |
| 2021-05-06 07:42 EST | News | Aravive EPS beats by $0.01, misses on revenue | N/A | |
| 2021-04-27 12:28 EST | News | Aravive shares rise after dosing first patient in late-stage ovarian cancer study | N/A | |
| 2021-03-18 16:06 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-18 14:18 EST | News | Unless Early Ovarian Data Is Oversold, Aravive Is Significantly Undervalued | N/A | |
| 2021-03-17 12:06 EST | Earnings Estimate | An EPS average of -$2.07 is estimated for the 2022 year. | Sell | |
| 2021-03-17 12:06 EST | Earnings Estimate | An EPS average of -$0.52 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-03-16 19:46 EST | News | Aravive EPS beats by $0.27, beats on revenue | N/A | |
| 2021-03-16 19:46 EST | News | Aravive shares rise on Q4 results, pipeline updates | N/A | |
| 2021-03-09 11:08 EST | Analyst Rating | The Analyst Target Price has increased from $21.33 to $22.5. | Buy | |
| 2021-03-08 17:53 EST | News | Aravive starts dosing in Phase 1b/2 AVB-500 cancer study | N/A | |
| 2021-03-08 17:53 EST | News | Aravive shares rise 8% as BTIG initiates with a buy | N/A | |
| 2021-01-04 11:09 EST | Analyst Rating | The Analyst Target Price has increased from $19.75 to $21.33. | Buy | |
| 2020-12-28 21:28 EST | News | Aravive: Pipeline-In-A-Pill In Oncology | N/A | |
| 2020-12-17 11:09 EST | Analyst Rating | The Analyst Target Price has decreased from $22.75 to $19.75. | Neutral | |
| 2020-12-13 03:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-19 11:22 EST | News | Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative | N/A | |
| 2020-11-15 11:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-11 12:48 EST | News | Aravive out-licenses cancer candidate AVB-500 in Greater China | N/A | |
| 2020-11-10 11:12 EST | Analyst Rating | The Analyst Target Price has decreased from $25.5 to $22.75. | Neutral | |
| 2020-11-09 19:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-09 11:12 EST | Analyst Rating | The Analyst Target Price has decreased from $27.75 to $25.5. | Neutral | |
| 2020-11-06 11:08 EST | Earnings Estimate | An EPS average of -$0.40 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-06 02:49 EST | News | Aravive EPS misses by $0.24 | N/A | |
| 2020-11-01 17:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-21 15:48 EST | News | Assessing An Investment In Aravive | N/A | |
| 2020-09-26 04:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-19 06:11 EST | News | William Blair initiates Aravive at Outperform due to AVB-500 | N/A | |
| 2020-08-07 12:10 EST | Financials | Company financials have been released. | Neutral | |
About Aravive, Inc (ARAV):
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
General
- Name Aravive, Inc
- Symbol ARAV
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 16
- Last Split Factor1:6
- Last Split Date2018-10-16
- Fiscal Year EndDecember
- IPO Date2014-03-21
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://aravive.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 22.8
- Price/Book (Most Recent Quarter) 3.36
- Enterprise Value Revenue 19.24
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.90
- Next Year EPS Estimate -$2.10
- Next Quarter EPS Estimate -$0.49
- Operating Margin -440%
- Return on Assets -21%
- Return on Equity -52%
- Revenue 5.69 million
- Earnings Per Share -$6.65
- Revenue Per Share $0.36
- Gross Profit -11935000
- Quarterly Earnings Growth -100%
View More
Highlights
- Market Capitalization 168.49 million
- EBITDA -23507000
- Analyst Target Price $22.5
- Book Value Per Share $2.92
View More
Share Statistics
- Shares Outstanding 19.66 million
- Shares Float 9.35 million
- % Held by Insiders 3017%
- % Held by Institutions 41%
- Shares Short 444777
- Shares Short Prior Month 560403
- Short Ratio 2.02
- Short % of Float 3%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 3.22
- 52 Week High $14.94
- 52 Week Low $3.65
- 50 Day Moving Average 6.8
- 200 Day Moving Average 5.83
View More
Dividends
- Dividend Date 2018-10-16
- ExDividend Date N/A
- Dividend Yield 0%
View More
Aravive, Inc (ARAV) Dividend Calendar:
ARAV's last dividend payment was made to shareholders on October 16, 2018.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Aravive, Inc (ARAV) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-25 | $5.69 million | -$0.25 | -$0.52 | 51.92% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.66 | -$0.42 | -58.65% |
| 2020-06-30 | 2020-08-03 | $N/A | -$0.32 | -$0.46 | 30.43% |
| 2020-03-31 | 2020-05-06 | $N/A | -$0.72 | -$0.36 | -102.82% |
| 2019-12-31 | 2020-03-27 | $N/A | -$0.35 | -$0.52 | 32.04% |
| 2019-09-30 | 2019-11-07 | $N/A | -$0.54 | -$0.50 | -7.29% |
| 2019-06-30 | 2019-08-07 | $3.05 million | -$0.27 | -$0.56 | 51.35% |
| 2019-03-31 | 2019-05-08 | $1.7 million | -$0.42 | -$0.86 | 51.16% |
| 2018-12-31 | 2019-03-07 | $1.37 million | -$4.82 | -$5.76 | 16.32% |
| 2018-09-30 | 2018-11-06 | $N/A | -$1.08 | -$5.76 | 81.17% |
| 2018-06-30 | 2018-08-07 | $N/A | -$1.62 | -$5.76 | 71.88% |
| 2018-03-31 | 2018-05-08 | $N/A | -$1.50 | -$5.16 | 70.93% |
| 2017-12-31 | 2018-03-01 | $40 million | $5.22 | -$7.20 | 172.5% |
| 2017-09-30 | 2017-10-26 | $N/A | -$8.40 | -$6.30 | -33.33% |
| 2017-06-30 | 2017-07-27 | $N/A | -$6.24 | -$5.15 | -21.21% |
| 2017-03-31 | 2017-04-27 | $N/A | -$5.10 | -$4.50 | -13.33% |
| 2016-12-31 | 2017-02-21 | $N/A | -$3.84 | -$4.86 | 20.99% |
| 2016-09-30 | 2016-11-03 | $N/A | -$5.52 | -$4.86 | -13.58% |
| 2016-06-30 | 2016-07-28 | $N/A | -$4.50 | -$5.17 | 12.93% |
| 2016-03-31 | 2016-04-28 | $N/A | -$4.92 | -$4.61 | -6.74% |
| 2015-12-31 | 2016-02-18 | $N/A | -$3.70 | -$4.21 | 12.02% |
| 2015-09-30 | 2015-10-29 | $N/A | -$0.69 | -$0.71 | 2.82% |
| 2015-06-30 | 2015-08-04 | $N/A | -$0.67 | -$0.63 | -6.35% |
| 2015-03-31 | 2015-05-06 | $N/A | -$0.79 | -$0.63 | -25.4% |
| 2014-12-31 | 2015-02-12 | $N/A | -$0.65 | -$0.44 | -47.73% |
| 2014-09-30 | 2014-11-06 | $N/A | -$0.57 | -$0.53 | -7.55% |
| 2014-06-30 | 2014-08-05 | $N/A | -$2.16 | -$2.67 | 19.1% |
| 2014-03-31 | 2014-05-05 | $N/A | -$56.64 | -$38.23 | -48.16% |
Aravive, Inc (ARAV) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 6.54 million | N/A | N/A | 3.49 million | N/A |
| Income Before Tax | -4.05 million | N/A | N/A | -10.8 million | N/A |
| Selling General Administrative | 3.2 million | N/A | N/A | 3.95 million | 2.65 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -3.82 million | N/A | N/A | -7.32 million | N/A |
| Operating Income | -4.05 million | N/A | N/A | -7.44 million | N/A |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | 5.69 million | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | -1000 | N/A | N/A | -3.57 million | N/A |
| Net Income From Continuing Operations | -4.05 million | N/A | N/A | -10.8 million | N/A |
| Net Income Applicable to Common Shares | -4.05 million | -10.66 million | -5.04 million | -10.8 million | N/A |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 792000 | -287000 | 110000 | N/A | 1.65 million |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | 33000 | 25.25 million | 1000 |
| Change to Operating Activities | -168000 | -1.82 million | 1.13 million | N/A | 162000 |
| Change in Cash | N/A | N/A | -4.43 million | 8.17 million | -3.4 million |
| Total Cash from Operating Activities | -6.3 million | -5.63 million | -4.46 million | N/A | -3.4 million |
| Depreciation | N/A | N/A | 125000 | 498000 | 125000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 3.29 million | 488000 | 4.97 million | N/A | 800000 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 19.66 million | N/A | N/A | 12.54 million | 13.07 million |
| Total Stockholder Equity | 48.06 million | N/A | N/A | 59 million | 69.05 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | 67.71 million | N/A | N/A | 71.54 million | 82.12 million |
| Common Stock | 48.06 million | 2000 | 2000 | 2000 | 2000 |
| Other Current Assets | 16000 | N/A | N/A | 95000 | 44000 |
| Retained Earnings | -500.65 million | -496.61 million | -485.95 million | -480.91 million | N/A |
| Other Liabilities | 6.32 million | 295000 | 295000 | 295000 | N/A |
| Other Assets | 4.21 million | 2.46 million | 3.04 million | 3.12 million | 3.18 million |
| Cash | 60.54 million | N/A | N/A | 60.7 million | 65.13 million |
| Total Current Liabilities | 4.82 million | 4.88 million | N/A | 4.96 million | 4.97 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 2.96 million | 3.21 million | 6.54 million | 6.96 million | 10.51 million |
| Total Current Assets | 60.54 million | 55.44 million | N/A | 61.28 million | 68.21 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 48.06 million | 49.24 million | 59.29 million | 58.82 million | N/A |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 4.82 million | 1.69 million | N/A | 1.19 million | N/A |
Aravive, Inc (ARAV) Chart:
Aravive, Inc (ARAV) News:
Below you will find a list of latest news for Aravive, Inc (ARAV) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Aravive, Inc (ARAV) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest ARAV Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 5:13 PM EST | 100 | $1.11 |
| Jun 13, 2022 5:27 PM EST | 100 | $1.1 |
| Jun 13, 2022 6:44 PM EST | 100 | $1.105 |
| Jun 13, 2022 7:33 PM EST | 100 | $1.1 |
| Jun 13, 2022 7:33 PM EST | 100 | $1.1 |
Aravive, Inc (ARAV) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1513818/000156459020031683/0001564590-20-031683-index.htm |
| 2020-07-01 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1513818/000000000020005925/0000000000-20-005925-index.htm |
| 2019-09-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924319023565/0000899243-19-023565-index.htm |
| 2019-10-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924319025300/0000899243-19-025300-index.htm |
| 2019-12-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924319028342/0000899243-19-028342-index.htm |
| 2019-12-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924319030048/0000899243-19-030048-index.htm |
| 2020-01-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320000904/0000899243-20-000904-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320000907/0000899243-20-000907-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320000912/0000899243-20-000912-index.htm |
| 2020-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320001969/0000899243-20-001969-index.htm |
| 2020-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320001973/0000899243-20-001973-index.htm |
| 2020-04-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320010586/0000899243-20-010586-index.htm |
| 2020-04-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320010588/0000899243-20-010588-index.htm |
| 2020-04-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320010589/0000899243-20-010589-index.htm |
| 2020-04-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320010591/0000899243-20-010591-index.htm |
| 2020-04-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320010626/0000899243-20-010626-index.htm |
| 2020-04-10 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320010642/0000899243-20-010642-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320015044/0000899243-20-015044-index.htm |
| 2020-09-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320025106/0000899243-20-025106-index.htm |
| 2020-09-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320025109/0000899243-20-025109-index.htm |
| 2020-09-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320025112/0000899243-20-025112-index.htm |
| 2020-09-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320025114/0000899243-20-025114-index.htm |
| 2020-09-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320025487/0000899243-20-025487-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320025488/0000899243-20-025488-index.htm |
| 2020-09-29 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320026472/0000899243-20-026472-index.htm |
| 2020-09-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1513818/000089924320026474/0000899243-20-026474-index.htm |
| 2020-04-16 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1513818/000110465920047074/0001104659-20-047074-index.htm |
| 2019-11-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1513818/000119312519301276/0001193125-19-301276-index.htm |
| 2019-11-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1513818/000119312519302500/0001193125-19-302500-index.htm |
| 2019-11-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000119312519302560/0001193125-19-302560-index.htm |
| 2019-12-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1513818/000119312519310233/0001193125-19-310233-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1513818/000119312520033446/0001193125-20-033446-index.htm |
| 2019-09-20 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1513818/000156459019035125/0001564590-19-035125-index.htm |
| 2019-09-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459019035618/0001564590-19-035618-index.htm |
| 2019-10-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459019036318/0001564590-19-036318-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459019041740/0001564590-19-041740-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1513818/000156459019041801/0001564590-19-041801-index.htm |
| 2019-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459019042168/0001564590-19-042168-index.htm |
| 2019-11-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459019043923/0001564590-19-043923-index.htm |
| 2019-12-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459019045046/0001564590-19-045046-index.htm |
| 2019-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459019046447/0001564590-19-046447-index.htm |
| 2020-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020000651/0001564590-20-000651-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020000896/0001564590-20-000896-index.htm |
| 2020-02-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020004909/0001564590-20-004909-index.htm |
| 2020-03-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020013387/0001564590-20-013387-index.htm |
| 2020-03-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1513818/000156459020013390/0001564590-20-013390-index.htm |
| 2020-03-27 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1513818/000156459020013400/0001564590-20-013400-index.htm |
| 2020-04-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020016124/0001564590-20-016124-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020021927/0001564590-20-021927-index.htm |
| 2020-05-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1513818/000156459020021944/0001564590-20-021944-index.htm |
| 2020-06-29 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1513818/000156459020030893/0001564590-20-030893-index.htm |
| 2020-07-02 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1513818/000156459020031683/0001564590-20-031683-index.htm |
| 2020-07-09 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1513818/000156459020032086/0001564590-20-032086-index.htm |
| 2020-07-14 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1513818/000156459020032350/0001564590-20-032350-index.htm |
| 2020-07-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020033133/0001564590-20-033133-index.htm |
| 2020-08-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020035506/0001564590-20-035506-index.htm |
| 2020-08-03 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1513818/000156459020035515/0001564590-20-035515-index.htm |
| 2020-08-05 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1513818/000156459020036198/0001564590-20-036198-index.htm |
| 2020-09-04 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1513818/000156459020042648/0001564590-20-042648-index.htm |
| 2020-09-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020042661/0001564590-20-042661-index.htm |
| 2020-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020043436/0001564590-20-043436-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020043602/0001564590-20-043602-index.htm |
| 2020-09-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020043768/0001564590-20-043768-index.htm |
| 2020-10-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020046127/0001564590-20-046127-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1513818/000156459020051374/0001564590-20-051374-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1513818/000156459020051375/0001564590-20-051375-index.htm |
| 2020-07-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1513818/999999999520001784/9999999995-20-001784-index.htm |
Aravive, Inc (ARAV) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aravive, Inc (ARAV). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 3017%Institutional Ownership: 4100%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-04-08 | Rekha Hemrajani | Insider | Sell | 42,750.00 | 14,250.00 | https://www.sec.gov/Archives/edgar/data/1513818/000089924320010591/0000899243-20-010591-index.htm | ||
| 2020-01-09 | Rekha Hemrajani | President and CEO | Buy | 57,000.00 | 57,000.00 | https://www.sec.gov/Archives/edgar/data/1513818/000089924320000907/0000899243-20-000907-index.htm | ||
| 2019-12-02 | SRINIVAS AKKARAJU | Director | Buy | 133,333.00 | 7.50 | 999,997.50 | 576,066.00 | https://www.sec.gov/Archives/edgar/data/1513818/000089924319028342/0000899243-19-028342-index.htm |
| 2020-04-08 | Jay Shepard | Insider | Sell | 9,291.00 | 61,201.00 | https://www.sec.gov/Archives/edgar/data/1513818/000089924320010588/0000899243-20-010588-index.htm | ||
| 2019-10-07 | Jay Shepard | President and CEO | Sell | 4,004.00 | 6.82 | 27,295.27 | 72,754.00 | https://www.sec.gov/Archives/edgar/data/1513818/000089924319025300/0000899243-19-025300-index.htm |